Cargando…

Incidence and outcomes of pulmonary hypertension in the Ireland

INTRODUCTION: Pulmonary hypertension (PH) is a progressive disease of the pulmonary vasculature, which is characterised by premature morbidity and mortality. The aim of this study is to define the characteristics of PH in the national PH unit (NPHU) in Ireland between 2010 and 2020. METHODS: Cases o...

Descripción completa

Detalles Bibliográficos
Autores principales: Cullivan, Sarah, Lennon, Denise, Meghani, Salima, Minnock, Caitriona, McCullagh, Brian, Gaine, Sean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244715/
https://www.ncbi.nlm.nih.gov/pubmed/35768152
http://dx.doi.org/10.1136/bmjresp-2022-001272
_version_ 1784738590318657536
author Cullivan, Sarah
Lennon, Denise
Meghani, Salima
Minnock, Caitriona
McCullagh, Brian
Gaine, Sean
author_facet Cullivan, Sarah
Lennon, Denise
Meghani, Salima
Minnock, Caitriona
McCullagh, Brian
Gaine, Sean
author_sort Cullivan, Sarah
collection PubMed
description INTRODUCTION: Pulmonary hypertension (PH) is a progressive disease of the pulmonary vasculature, which is characterised by premature morbidity and mortality. The aim of this study is to define the characteristics of PH in the national PH unit (NPHU) in Ireland between 2010 and 2020. METHODS: Cases of PH which were referred to the NPHU between 2010 and 2020 were included. PH was defined as a mean pulmonary artery pressure ≥25 mm Hg at right heart catheterisation. RESULTS: Four hundred and fifteen cases of PH were identified during the study period. Group 1 pulmonary arterial hypertension (PAH) accounted for 39% (n=163) of cases, with a calculated annual incidence of 3.11 per million population (95% CI 1.53 to 4.70). The leading PAH subgroup was connective tissue disease-associated PAH (CTD-PAH), which was responsible for 49% of PAH referrals. This was followed by idiopathic PAH, with an estimated annual incidence of 0.63 cases per million population. The mean age at PAH diagnosis was 56±15 years and 86% (n=111) received double-combination or triple-combination therapy within the first 12 months of diagnosis. The 1-year, 3-year and 5-year transplant-free survival for PAH was 89%, 75% and 65%. This was significantly lower for individuals with CTD-PAH relative to other PAH subgroups (p<0.05). DISCUSSION: This study describes the incidence and outcomes of PH in Ireland. While the outcomes are comparable to other centres, the incidence of PAH and specific subgroups appears low, suggesting that improved disease awareness and case recognition are required. Furthermore, the survival of individuals with CTD-PAH is poor and requires additional exploration.
format Online
Article
Text
id pubmed-9244715
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-92447152022-07-14 Incidence and outcomes of pulmonary hypertension in the Ireland Cullivan, Sarah Lennon, Denise Meghani, Salima Minnock, Caitriona McCullagh, Brian Gaine, Sean BMJ Open Respir Res Pulmonary Vasculature INTRODUCTION: Pulmonary hypertension (PH) is a progressive disease of the pulmonary vasculature, which is characterised by premature morbidity and mortality. The aim of this study is to define the characteristics of PH in the national PH unit (NPHU) in Ireland between 2010 and 2020. METHODS: Cases of PH which were referred to the NPHU between 2010 and 2020 were included. PH was defined as a mean pulmonary artery pressure ≥25 mm Hg at right heart catheterisation. RESULTS: Four hundred and fifteen cases of PH were identified during the study period. Group 1 pulmonary arterial hypertension (PAH) accounted for 39% (n=163) of cases, with a calculated annual incidence of 3.11 per million population (95% CI 1.53 to 4.70). The leading PAH subgroup was connective tissue disease-associated PAH (CTD-PAH), which was responsible for 49% of PAH referrals. This was followed by idiopathic PAH, with an estimated annual incidence of 0.63 cases per million population. The mean age at PAH diagnosis was 56±15 years and 86% (n=111) received double-combination or triple-combination therapy within the first 12 months of diagnosis. The 1-year, 3-year and 5-year transplant-free survival for PAH was 89%, 75% and 65%. This was significantly lower for individuals with CTD-PAH relative to other PAH subgroups (p<0.05). DISCUSSION: This study describes the incidence and outcomes of PH in Ireland. While the outcomes are comparable to other centres, the incidence of PAH and specific subgroups appears low, suggesting that improved disease awareness and case recognition are required. Furthermore, the survival of individuals with CTD-PAH is poor and requires additional exploration. BMJ Publishing Group 2022-06-29 /pmc/articles/PMC9244715/ /pubmed/35768152 http://dx.doi.org/10.1136/bmjresp-2022-001272 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Pulmonary Vasculature
Cullivan, Sarah
Lennon, Denise
Meghani, Salima
Minnock, Caitriona
McCullagh, Brian
Gaine, Sean
Incidence and outcomes of pulmonary hypertension in the Ireland
title Incidence and outcomes of pulmonary hypertension in the Ireland
title_full Incidence and outcomes of pulmonary hypertension in the Ireland
title_fullStr Incidence and outcomes of pulmonary hypertension in the Ireland
title_full_unstemmed Incidence and outcomes of pulmonary hypertension in the Ireland
title_short Incidence and outcomes of pulmonary hypertension in the Ireland
title_sort incidence and outcomes of pulmonary hypertension in the ireland
topic Pulmonary Vasculature
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244715/
https://www.ncbi.nlm.nih.gov/pubmed/35768152
http://dx.doi.org/10.1136/bmjresp-2022-001272
work_keys_str_mv AT cullivansarah incidenceandoutcomesofpulmonaryhypertensionintheireland
AT lennondenise incidenceandoutcomesofpulmonaryhypertensionintheireland
AT meghanisalima incidenceandoutcomesofpulmonaryhypertensionintheireland
AT minnockcaitriona incidenceandoutcomesofpulmonaryhypertensionintheireland
AT mccullaghbrian incidenceandoutcomesofpulmonaryhypertensionintheireland
AT gainesean incidenceandoutcomesofpulmonaryhypertensionintheireland